Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 619-370-5 | CAS number: 98725-11-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / micronucleus study
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 988
- Report date:
- 1988
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- not reported
- Qualifier:
- according to guideline
- Guideline:
- other: Abbreviated Japanese MOL/MHW/MITI Metaphase Analysis In CHO Cells In Vitro
- Version / remarks:
- not specified
- GLP compliance:
- not specified
- Type of assay:
- sister chromatid exchange assay in mammalian cells
Test material
- Reference substance name:
- 1,1'-(methylenedi-p-phenylene)bismaleimide
- EC Number:
- 237-163-4
- EC Name:
- 1,1'-(methylenedi-p-phenylene)bismaleimide
- Cas Number:
- 13676-54-5
- Molecular formula:
- C21H14N2O4
- IUPAC Name:
- 1,1'-[methylenedi(4,1-phenylene)]di(1H-pyrrole-2,5-dione)
- Test material form:
- solid: particulate/powder
Constituent 1
Method
Species / strain
- Species / strain / cell type:
- Chinese hamster Ovary (CHO)
- Details on mammalian cell type (if applicable):
- CELLS USED
- Source of cells: B.I.B.R.A. (British Industrial Biological Reasearch center)
- Suitability of cells: cells are recommended from OECD guideline
- Cell cycle length, doubling time or proliferation index: doubling time: 12-16 h
- Number of passages if applicable: 31
- Methods for maintenance in cell culture if applicable:
- Modal number of chromosomes: 20
MEDIA USED
- Type and identity of media including CO2 concentration if applicable: Nutrient medium - HAMS-F12 Gibco ltd. + 5% foetal bovine serum (Gibco), Lot-No.: 20G3373Y
- Properly maintained: yes - Additional strain / cell type characteristics:
- not specified
- Cytokinesis block (if used):
- Colcemid 0.1 µg/mL
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-Liver Mix
- Test concentrations with justification for top dose:
- 2.5, 5, 10 and 20 µg/mL based on the results from a preliminary study
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: test item is soluble in the vehicle
Controls
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- ethylmethanesulphonate
- Details on test system and experimental conditions:
- METHOD OF APPLICATION:
- Cell density at seeding (if applicable): 1E+05 cells/mL
DURATION
- Exposure duration: 24h without metabolic activation and 6h with metabolic activation
STAIN (for cytogenetic assays): 2% Gurrs Giemsa R66 for 5 min
SPINDLE INHIBITOR (cytogenetic assays): Demecolcine (0.1 µg/mL) for 2h
NUMBER OF METAPHASE SPREADS ANALYSED PER DOSE (if in vitro cytogenicity study in mammalian cells): first 100 consecutive well-spread metaphases from each culture were counted.
DETERMINATION OF CYTOTOXICITY
- Method: relative total growth
OTHER EXAMINATIONS:
- Determination of polyploidy: hyperploidy - Evaluation criteria:
- The range of abberation frequencies acceptable for control cultures:
i) Diploid cells with abberations (gaps included)
Range
Untreated controls 3-14
DMSO controls 2-10
Combined 2-14
S9-controls 2-6
S9/DMSO-controls 1-10
Combined 1-10
All controls 1-14
ii) Diploid cells with abberations (gaps included)
Range
Untreated controls 1-10
DMSO controls 0-7
Combined 0-10
S9-controls 1-3
S9/DMSO-controls 0-9
Combined 0-9
All controls 0-10
A positive response was recorded for a particular treatment if the % diploid cells with abberation (gaps excluded) exceeded the maximum historical value. If only the % diploid cells with abberations (gaps included) exceed historical values then +/- reponse was recorded. Positive responses were also recorded if the % cells with abberations (gaps excluded) was greater than twice the concurrent control level, even if it was below historical levels, but only if there was an indication of a dose response.
However, consideration is given to a number of factors, such as the frequency of chromosome exchange events which are comparatively rare in control cultures, and the ultimate designation must rely upon experience and sound scientific judgement (UKEMS Guidelines for Mutagenicity Testing, 1983).
Results and discussion
Test results
- Key result
- Species / strain:
- Chinese hamster Ovary (CHO)
- Metabolic activation:
- with and without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
Any other information on results incl. tables
Table 1: Results without S9 Mix
Treat-ment group |
Treatment time (hr) |
Concentration µg/mL |
No. diploid cells scored |
N |
% |
Judge-ment |
Gaps |
Chromatid |
Chromosome |
others |
Total No. cells with abberation |
Judgement |
|||||||||||||
|
g |
ctb |
cte |
csb |
cse |
X |
Z |
-g |
+g |
|
|||||||||||||||
Solvent control |
24 |
0 |
100 |
10 |
9.1 |
- |
1 |
1.5 |
0 |
0 |
0 |
0 |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
1 |
3 |
2.5 |
- |
100 |
11 |
9.9 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
||||||||||||||
200 |
21 |
9.5 |
3 |
0 |
0 |
2 |
0 |
0 |
0 |
2 |
5 |
||||||||||||||
Compimide 183 |
24 |
2.5 |
100 |
12 |
10.7 |
- |
1 |
3 |
2 |
1 |
0 |
0 |
2 |
3 |
1 |
1 |
0 |
0 |
2 |
1.5 |
5 |
5 |
6 |
8 |
+ |
100 |
8 |
7.4 |
5 |
0 |
0 |
4 |
1 |
0 |
1 |
5 |
10 |
||||||||||||||
200 |
20 |
9.1 |
6 |
2 |
0 |
6 |
2 |
0 |
3 |
10 |
16 |
||||||||||||||
5.0 |
100 |
17 |
14.5 |
- |
4 |
4 |
0 |
0 |
0 |
0 |
1 |
3 |
0 |
0 |
0 |
1 |
0 |
0.5 |
1 |
4 |
5 |
7.5 |
+ |
||
100 |
6 |
5.7 |
4 |
0 |
0 |
5 |
0 |
2 |
1 |
7 |
10 |
||||||||||||||
200 |
23 |
10.3 |
8 |
0 |
0 |
6 |
0 |
2 |
1 |
8 |
15 |
||||||||||||||
10.0 |
100 |
11 |
9.9 |
- |
7 |
5.5 |
0 |
2 |
1 |
1 |
9 |
6.3 |
0 |
0.5 |
0 |
0 |
1 |
3.5 |
10 |
9 |
15 |
13.5 |
+ |
||
100 |
8 |
7.4 |
4 |
4 |
1 |
4 |
1 |
0 |
6 |
8 |
12 |
||||||||||||||
200 |
19 |
8.7 |
11 |
4 |
2 |
|
1 |
0 |
7 |
18 |
27 |
||||||||||||||
20.0 |
100 |
9 |
8.3 |
- |
3 |
4.5 |
5 |
3.5 |
2 |
1.5 |
5 |
5 |
2 |
1 |
0 |
0.5 |
4 |
10.5 |
13 |
10 |
15 |
14 |
+ |
||
100 |
9 |
8.3 |
6 |
2 |
1 |
5 |
0 |
1 |
5 |
7 |
13 |
||||||||||||||
200 |
18 |
8.3 |
9 |
7 |
3 |
10 |
2 |
1 |
9 |
20 |
28 |
||||||||||||||
EMS |
24 |
1000 |
50 |
6 |
10.7 |
- |
22 |
36 |
17 |
29 |
21 |
36 |
14 |
33 |
3 |
6 |
4 |
7 |
0 |
0 |
43 |
76 |
44 |
83 |
+ |
50 |
3 |
5.7 |
14 |
12 |
15 |
19 |
3 |
3 |
0 |
33 |
39 |
||||||||||||||
100 |
9 |
8.3 |
36 |
29 |
36 |
33 |
6 |
7 |
0 |
76 |
83 |
Table 2: Results with S9 Mix
Treat-ment group |
Treatment time (hr) |
Concentration µg/mL |
No. diploid cells scored |
N |
% |
Judge-ment |
Gaps |
Chromatid |
Chromosome |
others |
Total No. cells with abberation |
Judgement |
|||||||||||||
|
g |
ctb |
cte |
csb |
cse |
X |
Z |
-g |
+g |
|
|||||||||||||||
Solvent control |
6 |
0 |
100 |
14 |
12.2 |
- |
6 |
5 |
1 |
1 |
1 |
1 |
3 |
3 |
0 |
0.5 |
0 |
0 |
0 |
0 |
5 |
5.5 |
11 |
10.5 |
- |
100 |
2 |
2.0 |
4 |
1 |
1 |
3 |
1 |
0 |
0 |
6 |
10 |
||||||||||||||
200 |
16 |
7.4 |
10 |
2 |
2 |
6 |
1 |
0 |
0 |
11 |
21 |
||||||||||||||
Compimide 183 |
6 |
2.5 |
100 |
10 |
9.1 |
- |
1 |
1 |
0 |
0 |
0 |
0 |
1 |
0.5 |
1 |
0.5 |
0 |
0 |
0 |
0 |
2 |
1 |
3 |
2 |
- |
100 |
8 |
7.4 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
||||||||||||||
200 |
18 |
8.3 |
2 |
0 |
0 |
1 |
1 |
0 |
0 |
2 |
4 |
||||||||||||||
5.0 |
100 |
6 |
5.7 |
- |
2 |
4 |
0 |
0.5 |
2 |
1.5 |
1 |
0.5 |
0 |
0 |
0 |
0 |
2 |
1 |
3 |
2 |
5 |
5.5 |
- |
||
100 |
6 |
5.7 |
6 |
1 |
1 |
0 |
0 |
0 |
0 |
1 |
6 |
||||||||||||||
200 |
12 |
5.7 |
8 |
1 |
3 |
1 |
0 |
00 |
2 |
4 |
11 |
||||||||||||||
10.0 |
100 |
11 |
9.9 |
- |
7 |
5 |
6 |
4 |
3 |
3.5 |
2 |
3.5 |
0 |
0.5 |
0 |
0 |
4 |
3 |
11 |
10 |
16 |
13.5 |
+ |
||
100 |
8 |
7.4 |
3 |
2 |
4 |
6 |
1 |
0 |
2 |
9 |
11 |
||||||||||||||
200 |
19 |
8.7 |
10 |
8 |
7 |
|
1 |
0 |
6 |
20 |
27 |
||||||||||||||
20.0 |
100 |
4 |
3.8 |
- |
7 |
6.5 |
8 |
5.5 |
2 |
4.5 |
4 |
4 |
0 |
1 |
0 |
0 |
8 |
8.5 |
11 |
13 |
17 |
18 |
+ |
||
100 |
6 |
5.7 |
6 |
3 |
7 |
4 |
2 |
0 |
9 |
15 |
19 |
||||||||||||||
200 |
10 |
4.8 |
13 |
11 |
9 |
8 |
2 |
0 |
17 |
26 |
36 |
||||||||||||||
CP |
6 |
25 |
50 |
8 |
13.8 |
- |
9 |
17 |
9 |
20 |
14 |
21 |
29 |
62 |
2 |
3 |
0 |
0 |
0 |
0 |
38 |
80 |
40 |
83 |
+ |
50 |
8 |
13.8 |
8 |
11 |
7 |
33 |
1 |
0 |
0 |
42 |
43 |
||||||||||||||
100 |
16 |
13.8 |
17 |
20 |
21 |
62 |
3 |
0 |
0 |
80 |
83 |
Applicant's summary and conclusion
- Conclusions:
- In the present study conducted according to OECD 473 CHO cells (1E+05 cells/mL) were treated with 2.5, 5.0, 10.0 and 20.0 µg/mL MDAB either 24 h without metabolic activation or 6 h with metabolic activation. MDAB produced significant, dose-related increases in the frequency of chromosome abberations both in the presence and in the absence of a liver enzyme metabolising system. The test item is therefore considered to be clastogenic to CHO cells in vitro.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
